CN110237261A - A kind of compound disintegrating agent and preparation method thereof - Google Patents
A kind of compound disintegrating agent and preparation method thereof Download PDFInfo
- Publication number
- CN110237261A CN110237261A CN201910692741.3A CN201910692741A CN110237261A CN 110237261 A CN110237261 A CN 110237261A CN 201910692741 A CN201910692741 A CN 201910692741A CN 110237261 A CN110237261 A CN 110237261A
- Authority
- CN
- China
- Prior art keywords
- disintegrating agent
- compound disintegrating
- preparation
- compound
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 39
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960000913 crospovidone Drugs 0.000 claims abstract description 14
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 14
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 14
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000811 xylitol Substances 0.000 claims abstract description 10
- 235000010447 xylitol Nutrition 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 10
- 229960002675 xylitol Drugs 0.000 claims abstract description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- 229930195725 Mannitol Natural products 0.000 claims abstract description 8
- 239000000594 mannitol Substances 0.000 claims abstract description 8
- 235000010355 mannitol Nutrition 0.000 claims abstract description 8
- 238000001694 spray drying Methods 0.000 claims abstract description 4
- 239000002002 slurry Substances 0.000 claims description 11
- 238000009826 distribution Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000010009 beating Methods 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 abstract description 5
- 229960001855 mannitol Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 241000331528 Chlorophytum capense Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000001033 granulometry Methods 0.000 description 2
- 238000005360 mashing Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005434 MCC/mannitol excipient Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of compound disintegrating agents and preparation method thereof, the component of compound disintegrating agent includes microcrystalline cellulose, mannitol, xylitol, calcium phosphate dibasic anhydrous, crospovidone, the above component is mixed by weight percentage, compound disintegrating agent is obtained by mixed pulp and spray drying, compound disintegrating agent provided by the invention is low by such environmental effects, disintegrating procedue more rapidly, thoroughly, meets the needs of market.
Description
Technical field
The present invention relates to drug auxiliary material fields, and in particular to a kind of compound disintegrating agent and preparation method thereof.
Background technique
In modern medicine, disintegrating agent is component part important in preparation, and wherein the quality and performance of disintegrating agent are to medicine
Quality plays the role of very important, the basis of the development of disintegrating agent even more preparation and dosage form development.
Disintegrating agent mainly applies to oral drug preparation, as in tablet, granule, capsule and Chinese patent drug pill,
Powder etc., main function mechanism be so that preparation is split the substance for being broken into fine particle rapidly in gastro-intestinal Fluid, thus make function at
Divide and dissolve and absorb rapidly, then through blood loop distribution at each position of body, scientific selection disintegrating agent is effective ingredient quilt
The premise reasonably absorbed, if the disintegrating property of preparation of traditional Chinese medicine composition is poor, the active constituent of drug cannot disappear
Change and effectively dissolved out in organ, to reduce the absorbent properties of effective component.
The disintegration ability of preparation of traditional Chinese medicine also suffers from such environmental effects, such as pH value, viscosity, tablet pressure, tablet
Hardness, so selecting one kind low by such environmental effects, more rapidly, thoroughly disintegrating agent is particularly important for disintegrating procedue.
Summary of the invention
In view of this, the present invention provide it is a kind of low by such environmental effects, disintegrating procedue more rapidly, thorough disintegrating agent,
And the preparation method of the disintegrating agent.
Technical scheme is as follows:
A kind of compound disintegrating agent, including following components in percentage by weight: microcrystalline cellulose 18%~23%, mannitol
55%~65%, xylitol 4%~8%, calcium phosphate dibasic anhydrous 4%~8%, crospovidone 6%~12%.
In one embodiment, the degree of polymerization of microcrystalline cellulose is 155-220；The average grain diameter of calcium phosphate dibasic anhydrous is 30
μm~90 μm；The average grain diameter of crospovidone is 3 μm~30 μm.
Above-mentioned compound disintegrating agent, preparation method are as follows:
A. mixed pulp: the group of above-mentioned weight percent being placed in and is beaten in tank, is added water, control revolving speed 200~
It 500 revs/min, is beaten and slurry is made；
B. be spray-dried: by slurry spray injection drying tower obtained by step a, control inlet air temperature is at 150-300 DEG C, outlet air
For temperature at 60~150 DEG C, material pump frequency is 20~50Hz, and atomizer frequency is 20~50Hz, and compound disintegrating agent is made.
In one embodiment, step a is calculated by 35%~55% solid content and water is added, and the concentration of the slurry is 35%
~48%.
In one embodiment, the beating time of step a is 1~3 hour.
In one embodiment, the revolving speed that step a is beaten tank is preferably 255~475 revs/min.
In one embodiment, the inlet air temperature of step b spray drying tower is preferably 170~230 DEG C, and leaving air temp is preferred
It is 85~115 DEG C.
In one embodiment, step b expects that pump frequency is preferably 25-47HZ, and atomizer frequency is preferably 28-42HZ.
In one embodiment, the compound disintegrating agent as made from above scheme, size distribution D10:15-35um, D50:
85-125um, D90:180-300um, bulk density 0.40-0.48g/cm3, plain piece, the plain piece suppressed with this compound disintegrating agent
Hardness 7-15kg, disintegration time limited are 33 seconds to 64 seconds.
Above-mentioned technical proposal has the following beneficial effects:
1. the degree of polymerization of microcrystalline cellulose and the proportion of microcrystalline cellulose, the partial size of anhydrous phosphoric acid light calcium, crospovidone
Distribution is all to influence the principal element of compound disintegrating agent disintegration effect；The microcrystalline cellulose for the use of the degree of polymerization being 155-220, it is average
The anhydrous calcium phosphate that partial size is 30 μm~90 μm, the crospovidone that average grain diameter is 3 μm~30 μm, can make compound disintegrating agent
Disintegration effect reaches best.
2. by suitably being matched between microcrystalline cellulose and mannitol, xylitol, crospovidone, calcium phosphate dibasic anhydrous
Manufactured compound disintegrating agent has good mouthfeel, low in hygroscopicity, by environmental factor (such as pH value, viscosity, tablet pressure, tablet
Hardness) influence extremely low effect.
3. calculating when slurrying by 35%-55% solid content and water being added, slurry will not be too dilute or too thick, makes to gather around when spray drying
There is good granulating effect, obtains uniform product.
Specific embodiment
For the ease of the understanding of those skilled in the art, below with reference to embodiment, the present invention is further illustrated, real
The content for applying example is not limitation of the invention.
Embodiment 1
A kind of compound disintegrating agent, including following components in percentage by weight:
Microcrystalline cellulose 22%, mannitol 62%, xylitol 4%, calcium phosphate dibasic anhydrous 4%, crospovidone 8%；
Wherein:
Microcrystalline cellulose: the degree of polymerization 195,
Mannitol: content 98%-102% pharmaceutical grade
Xylitol: content 98.5%-101% food grade
Calcium phosphate dibasic anhydrous；Density 0.81g/cm3, average grain diameter: 50 μm
Crospovidone: 30 μm of average grain diameter.
Embodiment 2
A kind of compound disintegrating agent, including following components in percentage by weight:
Microcrystalline cellulose 21%, mannitol 63%, xylitol 3%, calcium phosphate dibasic anhydrous 3%, crospovidone 10%；
Wherein:
Microcrystalline cellulose: the degree of polymerization 200,
Mannitol: content 98%-102% pharmaceutical grade
Xylitol: content 98.5%-101% food grade
Calcium phosphate dibasic anhydrous；Density 1.30g/cm3, average grain diameter: 70 μm
Crospovidone: 20 μm of average grain diameter.
Preparation method includes the following steps:
A. mixed pulp: compounding ingredients being placed in by weight percentage in mashing tank, calculates addition water by 45% solid content,
Revolving speed is controlled at 280 revs/min, is beaten 1 hour, the slurry that concentration is 45% is made；
B. be spray-dried: by slurry spray injection drying tower obtained by step a, control inlet air temperature is at 200 DEG C, leaving air temp
At 95 DEG C, material pump frequency is 30Hz, and atomizer frequency is 32Hz.
Size distribution D10:15um, D50:95um, D90:190um of compound disintegrating agent obtained, bulk density are
0.42g/cm3, disintegration time limited is 38 seconds.
Wherein:
Size distribution is detected using 3000 type laser granulometry of Malvern
Bulk density detection method:
1. above-mentioned microcrystalline cellulose powder about 25mL is taken to be added in dry 50mL graduated cylinder；
2. rotating graduated cylinder, powder is made to sink naturally, top is in a horizontal state, and reads powder volume V；
3. powder is all poured out and weighs weight m, bulk density=m/V.
Disintegration time limited detection method:
1. suitable 0.1mol/l hydrochloric acid solution is added into disintegration tester beaker, into beaker solution temperature reach 37
Degree；
2. the tablet being pressed into compound disintegrating agent is put into the sample cell of bracketplant, baffle is not added, opens lifting motor,
Move up and down hanging basket, timing；
3. after the disintegration of tablet in hanging basket all by the mesh screen of tube bottom when, then read access time, each pipe it is initial when
Between with disintegration time limited for after disintegration of tablet all by the time difference of mesh screen being the tablet.
Embodiment 3
A kind of compound disintegrating agent, including following components in percentage by weight:
Microcrystalline cellulose 20%, mannitol 60%, xylitol 5%, calcium phosphate dibasic anhydrous 5%, crospovidone 10%；
Wherein:
Microcrystalline cellulose: the degree of polymerization 210
Mannitol: content 98%-102% pharmaceutical grade
Xylitol: content 98.5%-101% food grade
Calcium phosphate dibasic anhydrous；Density 1.33g/cm3Average grain diameter: 60 μm
Crospovidone: average grain diameter: 15 μm.
Preparation method includes the following steps:
A. mixed pulp: compounding ingredients being placed in by weight percentage in mashing tank, calculates addition water by 45% solid content,
Revolving speed is controlled at 300 revs/min, is beaten 2 hours, the slurry that concentration is 40% is made；
B. be spray-dried: by slurry spray injection drying tower obtained by step a, control inlet air temperature is at 230 DEG C, leaving air temp
At 110 DEG C, material pump frequency is 40HZ, and atomizer frequency is 39HZ.
D10:30 μm of the size distribution of compound disintegrating agent obtained, D50:100 μm, D90:210 μm, bulk density are
0.45g/cm3, disintegration time limited is 36 seconds.
Wherein:
Size distribution is detected using 3000 type laser granulometry of Malvern
Bulk density detection method:
1. above-mentioned microcrystalline cellulose powder about 25mL is taken to be added in dry 50mL graduated cylinder；
2. rotating graduated cylinder, powder is made to sink naturally, top is in a horizontal state, and reads powder volume V；
3. powder is all poured out and weighs weight m, bulk density=m/V.
Disintegration time limited detection method:
1. suitable 0.1mol/l hydrochloric acid solution is added into disintegration tester beaker, into beaker solution temperature reach 37
Degree；
2. the tablet being pressed into compound disintegrating agent is put into the sample cell of bracketplant, baffle is not added, opens lifting motor,
Move up and down hanging basket, timing；
3. after the disintegration of tablet in hanging basket all by the mesh screen of tube bottom when, then read access time, each pipe it is initial when
Between with disintegration time limited for after disintegration of tablet all by the time difference of mesh screen being the tablet.
Above-described embodiment is the preferable implementation of the present invention, and in addition to this, the present invention can be existing with other way, not
Be detached from present inventive concept under the premise of it is any obviously replace it is within the scope of the present invention.
Claims (9)
1. a kind of compound disintegrating agent, which is characterized in that including following components in percentage by weight: microcrystalline cellulose 18%~
23%, mannitol 55%~65%, xylitol 4%~8%, calcium phosphate dibasic anhydrous 4%~8%, crospovidone 6%~
12%.
2. compound disintegrating agent as described in claim 1, it is characterised in that the degree of polymerization of the microcrystalline cellulose is 155~220；Nothing
The average grain diameter of water calcium monohydrogen phosphate is 30 μm~90 μm；The average grain diameter of crospovidone is 3 μm~30 μm.
3. compound disintegrating agent as described in claim 1, preparation method are as follows:
A. mixed pulp: the group of above-mentioned weight percent being placed in and is beaten in tank, and water is added, and controls revolving speed 200~500
Rev/min, it is beaten and slurry is made；
B. it is spray-dried: by slurry spray injection drying tower obtained by step a, controlling inlet air temperature at 150~300 DEG C, out wind-warm syndrome
For degree at 60~150 DEG C, material pump frequency is 20~50Hz, and atomizer frequency is 20~50Hz, and compound disintegrating agent is made.
4. the preparation method of compound disintegrating agent according to claim 3, which is characterized in that solid by 35%~55% in step a
Content, which calculates, is added water, and the concentration of the slurry is 35~48%.
5. the preparation method of compound disintegrating agent according to claim 3, which is characterized in that in step a, beating time is 1~3
Hour.
6. the preparation method of compound disintegrating agent according to claim 3, which is characterized in that in step a, the revolving speed for being beaten tank is
255~475 revs/min.
7. the preparation method of compound disintegrating agent according to claim 3, which is characterized in that in step b, spray drying tower into
Air temperature is 170~230 DEG C, and leaving air temp is 85~115 DEG C.
8. the preparation method of compound disintegrating agent according to claim 3, which is characterized in that in step b, material pump frequency be 25~
47 Hz, atomizer frequency are 28~42 Hz.
9. compound disintegrating agent according to claim 1, which is characterized in that size distribution D10 is 15~35um, D50 be 85~
125um, D90 are 180~300um, and bulk density is 0.4~0.48g/cm3, disintegration time limited is 33 seconds to 64 seconds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910692741.3A CN110237261A (en) | 2019-07-30 | 2019-07-30 | A kind of compound disintegrating agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910692741.3A CN110237261A (en) | 2019-07-30 | 2019-07-30 | A kind of compound disintegrating agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110237261A true CN110237261A (en) | 2019-09-17 |
Family
ID=67893754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910692741.3A Pending CN110237261A (en) | 2019-07-30 | 2019-07-30 | A kind of compound disintegrating agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110237261A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2595203A (en) * | 2020-03-03 | 2021-11-24 | Alkaloid Ad Skopje | Formulation |
| CN113876961A (en) * | 2021-09-28 | 2022-01-04 | 珠海市东辰制药有限公司 | Co-processing auxiliary material and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1523974A1 (en) * | 2003-10-15 | 2005-04-20 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
| US20100216885A1 (en) * | 2007-10-30 | 2010-08-26 | Catherine Kabaradjian | Orodispersible composition comprising polyunsaturated fatty acids without bad odor or taste |
| CN101829332A (en) * | 2010-05-27 | 2010-09-15 | 上海华茂药业有限公司 | Rapidly disintegrable pharmaceutic adjuvant and preparation method thereof |
-
2019
- 2019-07-30 CN CN201910692741.3A patent/CN110237261A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1523974A1 (en) * | 2003-10-15 | 2005-04-20 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
| US20100216885A1 (en) * | 2007-10-30 | 2010-08-26 | Catherine Kabaradjian | Orodispersible composition comprising polyunsaturated fatty acids without bad odor or taste |
| CN101829332A (en) * | 2010-05-27 | 2010-09-15 | 上海华茂药业有限公司 | Rapidly disintegrable pharmaceutic adjuvant and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2595203A (en) * | 2020-03-03 | 2021-11-24 | Alkaloid Ad Skopje | Formulation |
| CN113876961A (en) * | 2021-09-28 | 2022-01-04 | 珠海市东辰制药有限公司 | Co-processing auxiliary material and preparation method and application thereof |
| CN113876961B (en) * | 2021-09-28 | 2024-01-30 | 珠海市东辰制药有限公司 | Co-processing auxiliary material and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8153157B2 (en) | Porous cellulose aggregate and molding composition thereof | |
| AU2001267860B2 (en) | Cellulose powder | |
| JP4969104B2 (en) | Porous cellulose aggregate and molded body composition thereof | |
| JPH0573727B2 (en) | ||
| CN1823091B (en) | Functional starch powder | |
| CN110237261A (en) | A kind of compound disintegrating agent and preparation method thereof | |
| KR100587210B1 (en) | Solid medicinal preparations of multiphase structure for oral administration containing gatifloxacin and a process for preparing the same | |
| CN106389344A (en) | Calcium carbonate particles and preparation method thereof | |
| CN104288104A (en) | Oxcarbazepine dry suspension and preparation method thereof | |
| CN104758273B (en) | A kind of urea microcapsule formulation and preparation method thereof | |
| CN114129521A (en) | Calcium carbonate D3Granule and preparation method thereof | |
| CN105902564A (en) | Pharmaceutical composition for treating hypertension and preparation method thereof | |
| JP2005255619A (en) | Solid pharmaceutical preparation composition comprising sublimable active ingredient and porous cellulose particle | |
| JP2005255618A (en) | Solid pharmaceutical preparation composition comprising slightly water-soluble active ingredient and porous cellulose particle | |
| CN112791053B (en) | Hydrotalcite granules and preparation method thereof | |
| CN103181924B (en) | The preparation method of the general pyridine pharmaceutical composition of a kind of Lip river fluorine | |
| RU2259835C2 (en) | Method for preparing anti-inflammatory, wound-healing, capillary-strengthening and immunomodulating agent | |
| CN115569122B (en) | Donepezil Ji Huanshi implant and preparation method and application thereof | |
| JP2005255616A (en) | Solid pharmaceutical preparation composition comprising liquid or semi-solid active ingredient and porous cellulose aggregate particle | |
| CN101121696B (en) | Metal salt of pyritinol and hydrate of the same | |
| JP2005255617A (en) | Solid pharmaceutical preparation composition comprising fine particulate active ingredient and porous cellulose aggregate | |
| CN103599545B (en) | Drug-use coating composition containing modified starch and preparation method thereof | |
| JP2011026307A (en) | Core particle for pharmaceutical preparation | |
| CN117883388A (en) | Vitamin D3Granules and method for preparing same | |
| Li et al. | Optimization and application of porous core-shell particles for direct compaction. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |
|
| RJ01 | Rejection of invention patent application after publication |